

PRESS RELEASE
FOR IMMEDIATE RELEASE

CLARIFICATION :
PHARMANIAGA Q3FY2025 FINANCIAL PERFORMANCE

SHAH ALAM, 13 November 2025 – Pharmaniaga Berhad (Pharmaniaga or the Group) wishes to clarify recent media reports regarding the Group's financial results for the period ended 30 September 2025 (Q3 FY2025), announced to Bursa Malaysia today.

For Q3 FY2025, the Group recorded a Profit After Tax (PAT) of RM7.5 million. While this reflects a decrease from RM101.3 million in the corresponding quarter last year, the prior period included a one-off penalty waiver of RM94.9 million (net of tax) from the Government. The penalty waiver was related to Pharmaniaga Logistics Sdn Bhd's non-fulfilment of certain performance standards specified in the previous concession agreement, caused by Movement Control Order during the COVID-19 pandemic period.

Excluding the one-off penalty waiver of RM124.9 million in the previous financial year, the Group recorded a solid underlying revenue growth of 11.3% compared with the corresponding quarter last year. Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for Q3 FY2025 stood at RM32.7 million, indicating stable underlying profitability.

Overall, the Group delivered stronger performance in Q3 FY2025 compared to the previous year, underpinned by enhanced operational efficiencies, disciplined cost optimisation efforts, and the absence of one-off item in the current reporting period.

We trust this provides clarity on the differences in the reported results.

-END-

About Pharmaniaga Berhad

Pharmaniaga is the pharmaceutical arm of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the substantial shareholders of the Company. Listed on the Main Market of Bursa Malaysia Securities Berhad, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products. With a vision to be the premier Malaysian pharmaceutical company, its operations are strengthened by five manufacturing plants, as well as extensive logistics and distribution network in Malaysia and Indonesia. Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical industry.

For more information, please visit <https://pharmaniaga.com/>.

Issued by Imej Jiwa Sdn Bhd on behalf of Pharmaniaga Berhad

[For further media inquiries please contact:](#)

Dato' Zuhri Iskandar Kamarzaman (Pharmaniaga)

E-mail: zuhri@pharmaniaga.com

Telephone number: 03-3342 9999 ext. 434

Elizabeth Tan (Imej Jiwa)

E-mail: elizabeth@imejjiwa.com | Mobile: +6012 207 0993